LitAlert ~~ GeneLit.com

    • BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
    • Lips EH, Benard-Slagter A, Opdam M, Scheerman CE, Wesseling J, Hogervorst FBL, Linn SC, Savola S, Nederlof PM.
    • Breast Cancer Res. 2020 Jul 25;22(1):79. doi: 10.1186/s13058-020-01313-7.
    • PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.
    • Lee EK, Matulonis UA.
    • Cancers (Basel). 2020 Jul 25;12(8):E2054. doi: 10.3390/cancers12082054.
    • Male breast cancer risk assessment and screening recommendations in high risk men who undergo genetic counseling and multi-gene panel testing (MGPT).
    • Gaddam S, Heller SL, Babb JS, Gao Y.
    • Clin Breast Cancer. 2020 Jul 25:S1526-8209(20)30180-4. doi: 10.1016/j.clbc.2020.07.014. Epub ahead of print.
    • Whether, when, and how to communicate genetic risk to minors: 'I wanted more information but I think they were scared I couldn't handle it'.
    • Stuttgen K, McCague A, Bollinger J, Dvoskin R, Mathews D.
    • J Genet Couns. 2020 Jul 23. doi: 10.1002/jgc4.1314. Epub ahead of print.
    • BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study.
    • Kitson SJ, Bafligil C, Ryan NAJ, Lalloo F, Woodward ER, Clayton RD, Edmondson RJ, Bolton J, Crosbie EJ, Evans GD.
    • Eur J Cancer. 2020 Jul 19;136:169-175. doi: 10.1016/j.ejca.2020.05.030. Epub ahead of print.